20 years on paper. The real story is longer—and it matters.
Most people hear “drug patent duration” and assume the clock starts, runs for 20 years, and ends cleanly. In practice, the timeline is more like a relay race—multiple legal instruments, regula…
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States Read Post »
Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing often isn’t science—it’s paperwork, timing, and precision.
A single misstep in patent …
South America’s drug patent map is no longer a “nice-to-know.” It’s a competitive advantage.
If you’re building a pipeline, negotiating partnerships, or planning launches, you can’t afford to treat patent landscapes as a single global spreadsheet. The …
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Most 505(b)(2) strategies fail—not because the science is wrong, but because the business model is.
If you’re a CDMO, specialty lab, or development partner supporting 505(b)(2) follow-on drugs, you already know the pitch: leverage existing data, reduce…
Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/
DrugChatter: What are the effects of combining lipitor and aspirin? Read Post »
Pharma doesn’t just defend patents anymore—it builds a stack.
In a recent DrugPatentWatch post, the core idea is blunt: companies can “layer” exclusivity protections—like New Chemical Entity (NCE) and orphan drug exclusivity—around a product to make ge…
India’s “drug patent clock” isn’t a clock at all—it’s a maze. Here’s how long protection really lasts.
If you’ve ever heard that a drug patent in India “lasts 20 years,” you’ve heard the headline—not the reality.
In practice, the effective protection w…
Generic drugs are racing—again. And the rules of the road are changing faster than most investors realize.
If you’ve been watching the generic market from the sidelines, you might think the story is simple: patents expire, generics launch, prices fall,…
Biopharma’s biggest “race” isn’t R&D—it’s the tender window.
If you’re a commercial market access vendor, a business development leader, or a biopharma operator trying to land EU formulary wins, here’s the uncomfortable truth: the most valuable t…
Biopharma talent is moving—and the next destination isn’t a mystery.
It’s showing up in the unglamorous, high-stakes arena where careers are quietly being shaped: biosimilar patent wars.
A new DrugPatentWatch piece lays out a pattern that many in the i…
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
Get new actionable insights and updates from BiotechBlog
